Filing summary
Identity note: The supplied filing is for Pieris Pharmaceuticals, Inc., not “Palvella Therapeutics, Inc.” It is a Form 10-Q for the quarter ended March 31, 2021, filed May 17, 2021. Confirm the intended company before relying on this summary.
Business context and reporting period
Pieris is a clinical-stage biotechnology company developing Anticalin-based medicines. Its principal programs include PRS-060/AZD1402 for asthma, partnered with AstraZeneca, and cinrebafusp alfa, an immuno-oncology candidate. The company had no product sales; reported revenue came from collaborations and licenses.
Financial performance and liquidity
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Total revenue | $15.6 million | $13.3 million; up $2.4 million |
| Research and development expense | $16.6 million | $12.8 million; up $3.8 million |
| General and administrative expense | $4.1 million | $4.4 million; down $0.2 million |
| Operating loss | $5.1 million | $3.9 million |
| Net loss | $4.2 million | $3.6 million |
| Basic and diluted loss per share | $0.07 | $0.07 |
| Net cash used in operations | $12.1 million | $15.1 million |
| Cash and cash equivalents at quarter-end | $66.8 million | $70.4 million at December 31, 2020 |
Revenue included a $13.0 million AstraZeneca milestone for initiation of the PRS-060/AZD1402 Phase 2a study. Customer revenue was $14.9 million versus $8.9 million; collaboration revenue was $0.8 million versus $4.4 million. The company reported no product-sale revenue, so conventional product gross margins are not applicable; revenue remained below operating expenses.
Current assets were $88.3 million and current liabilities $30.3 million at March 31, 2021. Total liabilities were $77.6 million, primarily deferred revenue and operating lease liabilities; the filing does not report borrowings or other financial debt. Accumulated deficit was $215.6 million. Cash declined $3.6 million during the quarter, including $9.7 million of financing cash inflow, mainly from the Seagen share issuance.
Material changes and significant events
- Revenue rose year over year mainly because of the AstraZeneca Phase 2a milestone; lower Servier collaboration revenue partly offset the increase.
- R&D expense increased 30%, chiefly from higher immuno-oncology manufacturing costs and proprietary respiratory preclinical work.
- On March 24, Pieris amended its Seagen collaboration and entered a combination-study agreement for cinrebafusp alfa with Seagen’s tucatinib. Seagen also agreed to buy $13.0 million of Pieris shares; the financing generated $9.7 million net proceeds in Q1.
- On March 29, Pieris amended its AstraZeneca agreements, restructuring PRS-060/AZD1402 commercial economics while maintaining the stated overall value split. AstraZeneca agreed to purchase $10.0 million of shares; that transaction closed April 1.
- After quarter-end, Pieris signed an exclusive worldwide PRS-342 license with Boston Pharmaceuticals on April 24, providing a $10.0 million upfront payment and eligibility for up to $352.5 million in development, regulatory and sales milestones, plus royalties.
- As of March 31, the $13.0 million AstraZeneca milestone and the $10.0 million AstraZeneca share purchase had not been reflected in quarter-end cash. Management also identified the Boston upfront payment as due after quarter-end.
Outlook, risks, and contingencies
Management expected continued operating losses for at least several years and increasing cash requirements as clinical and preclinical programs advance. It stated that available funds, including expected near-term receipts, were expected to fund operations for at least 12 months from the report date; this estimate is subject to uncertainty. Pieris may seek equity financing, ATM sales, collaborations, licenses, milestones, or debt, and warns that acceptable financing may not be available and could dilute shareholders.
Clinical and regulatory outcomes, trial timing, manufacturing and third-party dependence, collaboration performance, intellectual-property protection, competition, foreign-exchange movements, and COVID-19 effects on research, supply chains, and trials are key risks. Cinrebafusp alfa’s partial FDA clinical hold was lifted in January 2021; Pieris planned a two-arm Phase 2 gastric-cancer study for summer 2021. The company also anticipated initiating a Phase 1 study of PRS-344 in 2021. No material pending legal proceedings or material changes to previously disclosed risk factors were reported.
Most important facts to verify
- Confirm the intended registrant: the filing is Pieris Pharmaceuticals, not Palvella Therapeutics.
- Verify collection and timing of the $13.0 million AstraZeneca milestone and the April $10.0 million AstraZeneca share proceeds, and receipt of the Boston Pharmaceuticals upfront payment.
- Assess how much reported revenue depends on milestones and collaboration accounting rather than recurring product sales.
- Review the assumptions underlying management’s 12-month cash runway and the need for future financing.
- Track clinical progress, safety and efficacy evidence for PRS-060/AZD1402 and cinrebafusp alfa, and the planned PRS-344 study.
- Reconcile share dilution: 59.7 million common shares were outstanding at March 31, while 63.3 million were reported outstanding as of May 12, 2021.